{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"lutetium Lu 177-DOTATATE"},{"type":"Abbreviation","name":"177 Lu-DOTA-TATE"},{"type":"Synonym","name":"177 Lu-DOTA-Tyr3-octreotate"},{"type":"Synonym","name":"lutetium oxodotreotide LU-177"},{"type":"USBrandName","name":"Lutathera"},{"type":"Synonym","name":"177Lu-DOTA0-Tyr3-Octreotate"},{"type":"CASRegistryName","name":"437608-50-9"},{"type":"Synonym","name":"lutetium Lu 177 DOTA(0)-Tyr(3)-octreotate"},{"type":"Synonym","name":"lutetium Lu 177-DOTA-Tyr3-octreotate"}],"definition":{"html":"A radioconjugate consisting of the tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential imaging and antineoplastic activities. Lutetium Lu 177 dotatate binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Tyr3-octreotate (TATE) is an octreotide derivative in which phenylalanine at position 3 is substituted by tyrosine and position 8 threoninol is replaced with threonine. SSTRs have been shown to be present in large numbers on NET and their metastases, while most other normal tissues express low levels of SSTRs.","text":"A radioconjugate consisting of the tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential imaging and antineoplastic activities. Lutetium Lu 177 dotatate binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Tyr3-octreotate (TATE) is an octreotide derivative in which phenylalanine at position 3 is substituted by tyrosine and position 8 threoninol is replaced with threonine. SSTRs have been shown to be present in large numbers on NET and their metastases, while most other normal tissues express low levels of SSTRs."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/lutetiumLu177-dotatate","text":"Lutetium Lu 177-Dotatate"},"nciConceptId":"C95020","nciConceptName":"Lutetium Lu 177 Dotatate","termId":715523,"name":"lutetium Lu 177 dotatate","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-dotatate"}],"links":null}